Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Kenya High Court overturns Anti-Counterfeit Law finding it may interfere with access to legal generic medicines (IP Watch) (IP Watch) (Afro-IP) (Michael Geist)

Yasmin (Ethinyl estradiol, Drospirenone) – US: CAFC affirms dismissal of Bayer’s inducement claims in Yasmin case: Bayer Schering Pharma et al. v. Lupin et al (Orange Book Blog) (Patent Docs) (FDA Law Blog)

Prandin (Repaglinide) – US: Caraco Pharmaceutical v. Novo Nordisk: Supreme Court rules that generic pharmaceutical companies can counterclaim in patent cases to correct “use codes” (Maryland Intellectual Property Law Blog) (Patent Docs) (Pharma Patents)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

The WHO’s final sprint toward an international convention on R&D (IP Watch)

India: Hahnemann alleges trademark infringement of homeopathic medicines before the Calcutta High Court (Spicy IP)

Kenya High Court overturns Anti-Counterfeit Law finding it may interfere with access to legal generic medicines (IP Watch) (IP Watch) (Afro-IP) (Michael Geist)

Nigeria: NAFDAC, trade marks and trade reps in Nigeria: Some guidance (Afro-IP)

US: Senate HELP Committee markup of FDA bills on Wednesday, April 25, 2012 (KEI)

US: Congress introduces the PATIENTS’ FDA Act to increase transparency, efficiency, and predictability (FDA Law Blog)

US: Senate and House Bills seek to legislatively overturn the supreme court’s Mensing decision (FDA Law Blog)

US: ALJ Rogers denies motion to supplement notice of prior art in Certain Coenzyme Q10 Products (337-TA-790) (ITC 337 Law Blog)

US: Precision BioSciences files patent infringement suit against Cellectis over meganucleases targeting the HIV1 genome (Patent Docs)

US: Otsuka files for PTA calculation review for patent entitled “5-HT1A Receptor Subtype Agonist” (Patent Docs)

US: Incyte files for PTA calculation review concerning its patent entitled “Modulators of Indoleamine 2,3-Dioxygenase and Methods of Using the Same” (Patent Docs)

US: Enzo Life Sciences files patent infringement suits against Affymetrix, Agilent and Illumina based on their nucleic acid arrary products (Patent Docs)

 

Products

Acular LS (Ketorolac tromethamine) – US: Allergan files separate patent infringement suits against Akorn, Alcon and Apotex based on their generic versions of Acular LS (Patent Docs)

Argatroban  – US: Eagle Pharmaceuticals files patent infringement suit against Sandoz in response to Para IV challenge (Patent Docs)

Argatroban – US: Glaxosmithkline files patent infringement suit against Hikma in response to Para IV certification filing (Patent Docs)

Atripla (Emtricitabine, Tenofovir, Efavirenz) – Poland: Recent ruling on “product” and claim construction (The SPC Blog)

Botox (Botulinum) – EU: Mengozzi AG opines evidence of parasitic intent not unfounded: L’Oreal appeal denied: C-100/11 Helena Rubinstein and L’Oreal v OHIM (IP Osgoode)

Cetrorelix – UK: Late renewal: when the computer can’t be blamed: Tulane Education Fund v Comptroller General of Patents (The SPC Blog)

Colcrys (Colchicine) – US: AR Holdings files patent infringement suit against Par Pharmaceuticals in response to ANDA filing (Patent Docs)

Copaxone (Glatiramer) – US: Teva files patent infringement suit against Synthon in response to Para IV challenge (Patent Docs)

Copaxone (Glatiramer) – US: Teva files patent infringement suit against Synthon in response to Para IV certification filing (Patent Docs)

Crestor (Rosuvastatin) – CAFC: Section viii statements – Still a viable route to generic approval where the application is not claimed in an Orange Book patent: AstraZeneca v Apotex (Intellectual Property Law Blog)

Eloxatin (Oxaliplatin) – US: Sanofi files patent infringement suit against Strides following Para IV challenge (Patent Docs)

Humira (Adalimumab) – US: Abbott asks FDA to refuse certain biosimilar applications (Patent Docs)

Latisse (Bimatoprost) – US: Allergan files patent infringement suit against Watson in response to ANDA filing (Patent Docs)

Minirin (Desmopressin) – US: Ferring files suit against Allergan seeking correction of inventorship (Patent Docs)

Prandin (Repaglinide) – US: Caraco Pharmaceutical v. Novo Nordisk: Supreme Court rules that generic pharmaceutical companies can counterclaim in patent cases to correct “use codes” (Maryland Intellectual Property Law Blog) (Patent Docs) (Pharma Patents)

Xalatan (Latanoprost) – Italy: Beware of competition law! Relying on patents to extend protection for medicines may be anticompetitive: Ratiopharm v Pfizer (JIPLP)

Yasmin (Ethinyl estradiol, Drospirenone) – US: CAFC affirms dismissal of Bayer’s inducement claims in Yasmin case: Bayer Schering Pharma et al. v. Lupin et al (Orange Book Blog) (Patent Docs) (FDA Law Blog)